'The end' - or is it? Emergence of SARS-CoV-2 EG.5 and BA.2.86 subvariants

doi:10.2217/fvl-2023-0150

Editorial

. 2023 Sep:10.2217/fvl-2023-0150.

doi: 10.2217/fvl-2023-0150. Epub 2023 Sep 19.

'The end' - or is it? Emergence of SARS-CoV-2 EG.5 and BA.2.86 subvariants

Farid Rahimi¹, Mohammad Darvishi², Amin Talebi Bezmin Abadi³

Affiliations

¹ Research School of Biology, The Australian National University, Ngunnawal & Ngambri Country, Canberra, ACT, 2600, Australia.
² Infectious Diseases & Tropical Medicine Research Center (IDTMRC), Department of Aerospace & Subaquatic Medicine, AJA University of Medicinal Sciences, Tehran, 1411718541, Iran.
³ Department of Bacteriology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, 14115-111, Iran.

PMID: 37736262
PMCID: PMC10511002
DOI: 10.2217/fvl-2023-0150

Editorial

'The end' - or is it? Emergence of SARS-CoV-2 EG.5 and BA.2.86 subvariants

Farid Rahimi et al. Future Virol. 2023 Sep.

. 2023 Sep:10.2217/fvl-2023-0150.

doi: 10.2217/fvl-2023-0150. Epub 2023 Sep 19.

Authors

Farid Rahimi¹, Mohammad Darvishi², Amin Talebi Bezmin Abadi³

Affiliations

¹ Research School of Biology, The Australian National University, Ngunnawal & Ngambri Country, Canberra, ACT, 2600, Australia.
² Infectious Diseases & Tropical Medicine Research Center (IDTMRC), Department of Aerospace & Subaquatic Medicine, AJA University of Medicinal Sciences, Tehran, 1411718541, Iran.
³ Department of Bacteriology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, 14115-111, Iran.

PMID: 37736262
PMCID: PMC10511002
DOI: 10.2217/fvl-2023-0150

No abstract available

Keywords: COVID-19; COVID-19 pandemic; COVID-19 vaccine; SARS-CoV-2 variants; variants of concern.

PubMed Disclaimer

Conflict of interest statement

Conflict of interests disclosure The authors have no competing interests or relevant affiliations with any organization or entity with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

Cited by

Development and Validation of a Robust and Interpretable Early Triaging Support System for Patients Hospitalized With COVID-19: Predictive Algorithm Modeling and Interpretation Study.
Baek S, Jeong YJ, Kim YH, Kim JY, Kim JH, Kim EY, Lim JK, Kim J, Kim Z, Kim K, Chung MJ. Baek S, et al. J Med Internet Res. 2024 Jan 11;26:e52134. doi: 10.2196/52134. J Med Internet Res. 2024. PMID: 38206673 Free PMC article.
Immunogenicity of Tetravalent Protein Vaccine SCTV01E-2 against SARS-CoV-2 EG.5 Subvaraint: A Phase 2 Trial.
Tang J, Xu Q, Zhu C, Xuan K, Li T, Li Q, Pang X, Zha Z, Li J, Qiao L, Xu H, Wu G, Tian Y, Han J, Gao C, Yi J, Qian G, Tian X, Xie L. Tang J, et al. Vaccines (Basel). 2024 Feb 8;12(2):175. doi: 10.3390/vaccines12020175. Vaccines (Basel). 2024. PMID: 38400158 Free PMC article.
ACE2 and TMPRSS2 genetic polymorphisms as potential predictors of COVID-19 severity and outcome in females.
Matic S, Milovanovic D, Mijailovic Z, Djurdjevic P, Stefanovic S, Todorovic D, Vitosevic K, Canovic V, Popovic S, Dimitrijevic NM, Zivanovic M, Seklic D, Aleksic S, Djordjevic N, Vukic M, Vukovic N, Filipovic N, Baskic D, Djordjevic N. Matic S, et al. Front Med (Lausanne). 2024 Dec 18;11:1493815. doi: 10.3389/fmed.2024.1493815. eCollection 2024. Front Med (Lausanne). 2024. PMID: 39744525 Free PMC article.
Virological Characteristics of Five SARS-CoV-2 Variants, Including Beta, Delta and Omicron BA.1, BA.2, BA.5.
Zeng Y, Xia F, Guo C, Hu C, Li Y, Wang X, Wu Q, Chen Z, Lu J, Wang Z. Zeng Y, et al. Viruses. 2023 Dec 8;15(12):2394. doi: 10.3390/v15122394. Viruses. 2023. PMID: 38140635 Free PMC article.
The characterization of technical design of a virus-like structure (VLS) nanodelivery system as vaccine candidate against SARS-CoV-2 variants.
Zhang J, Zeng F, Li Y, Mu C, Liu C, Wang L, Peng X, He L, Su Y, Li H, Wang A, Feng L, Gao D, Zhang Z, Xu G, Wang Y, Yue R, Si J, Zheng L, Zhang X, He F, Yi H, Tang Z, Li G, Ma K, Li Q. Zhang J, et al. Hum Vaccin Immunother. 2025 Dec;21(1):2473183. doi: 10.1080/21645515.2025.2473183. Epub 2025 Mar 5. Hum Vaccin Immunother. 2025. PMID: 40045463 Free PMC article.

See all "Cited by" articles

References

1. Chan JF, Kok KH, Zhu Z et al. Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. Emerg Microbes Infect. 9(1), 221–236 (2020). - PMC - PubMed
1. Chavda VP, Bezbaruah R, Deka K, Nongrang L, Kalita T. The Delta and Omicron Variants of SARS-CoV-2: what we know so far. Vaccines (Basel). 10(11), 1926 (2022). - PMC - PubMed
1. Markov PV, Ghafari M, Beer M et al. The evolution of SARS-CoV-2. Nat. Rev. Microbiol. 21(6), 361–379 (2023). - PubMed
1. Singh D, Yi SV. On the origin and evolution of SARS-CoV-2. Exp. Mol. Med. 53(4), 537–547 (2021). - PMC - PubMed
1. Kupferschmidt K, Wadman M. End of COVID-19 emergencies sparks debate. Science 380(6645), 566–567 (2023). - PubMed

Publication types

Actions

LinkOut - more resources

Full Text Sources
- Europe PubMed Central
- PubMed Central
Miscellaneous
- NCI CPTAC Assay Portal

[1] Chan JF, Kok KH, Zhu Z et al. Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. Emerg Microbes Infect. 9(1), 221–236 (2020). - PMC - PubMed

[2] Chan JF, Kok KH, Zhu Z et al. Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. Emerg Microbes Infect. 9(1), 221–236 (2020). - PMC - PubMed

[3] Chavda VP, Bezbaruah R, Deka K, Nongrang L, Kalita T. The Delta and Omicron Variants of SARS-CoV-2: what we know so far. Vaccines (Basel). 10(11), 1926 (2022). - PMC - PubMed

[4] Chavda VP, Bezbaruah R, Deka K, Nongrang L, Kalita T. The Delta and Omicron Variants of SARS-CoV-2: what we know so far. Vaccines (Basel). 10(11), 1926 (2022). - PMC - PubMed

[5] Markov PV, Ghafari M, Beer M et al. The evolution of SARS-CoV-2. Nat. Rev. Microbiol. 21(6), 361–379 (2023). - PubMed

[6] Markov PV, Ghafari M, Beer M et al. The evolution of SARS-CoV-2. Nat. Rev. Microbiol. 21(6), 361–379 (2023). - PubMed

[7] Singh D, Yi SV. On the origin and evolution of SARS-CoV-2. Exp. Mol. Med. 53(4), 537–547 (2021). - PMC - PubMed

[8] Singh D, Yi SV. On the origin and evolution of SARS-CoV-2. Exp. Mol. Med. 53(4), 537–547 (2021). - PMC - PubMed

[9] Kupferschmidt K, Wadman M. End of COVID-19 emergencies sparks debate. Science 380(6645), 566–567 (2023). - PubMed

[10] Kupferschmidt K, Wadman M. End of COVID-19 emergencies sparks debate. Science 380(6645), 566–567 (2023). - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

'The end' - or is it? Emergence of SARS-CoV-2 EG.5 and BA.2.86 subvariants

Affiliations

'The end' - or is it? Emergence of SARS-CoV-2 EG.5 and BA.2.86 subvariants

Authors

Affiliations

Conflict of interest statement

Similar articles

Cited by

References

Publication types

LinkOut - more resources

Full Text Sources

Miscellaneous